Perifosine
- Generic Name
- Perifosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H52NO4P
- CAS Number
- 157716-52-4
- Unique Ingredient Identifier
- 2GWV496552
- Background
Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.
- Indication
Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019656
- Locations
- 🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath